Human T-cell lymphotropic virus type I (HTLV-I) proviral integration status was examined by Southern blot analysis in peripheral blood mononuclear cell (PBMC) DNA from patients presenting a tropical spastic paraparesis (TSP) and serological evidence of HTLV-I infection. Surface phenotype and morphological aspects of PBMC were also studied. A polyclonal HTLV-I proviral integration was found in the PBMC of the 10 patients studied irrespective of their geographical origin (French West Indies, French Guiana. and Africa), the duration of their clinical illness, or the HTLV-I antibody titer. Furthermore, by dilution experiments and hypothesizing that only one copy of HTLV-I proviral DNA is present in one cell, we estimated that this UMAN T-CELL lymphotropic virus type I (HTLV-H I)',' is a type C retrovirus etiologically linked with adult T-cell leukemia/lymphoma (ATL), a lymphoproliferative malignancy characterized by a clonal expansion of CD4+ lymphocytes and a monoclonal integration of HTLV-I in the leukemic cell^.^.^ In 1985 some of us5 showed the presence of specific HTLV-I antibodies in serum and cerebrospinal fluid (CSF) of patients from Martinique (French West Indies) having a chronic progressive myelopathy referred to as tropical spastic paraparesis (TSP) and suggested that HTLV-I, or a closely related virus, could be the etiological agent of this neuromyelopathy, frequently occurring in tropical areas. Subsequent reports have confirmed these findings in patients from Colombia: Jamaica: the Seychelles Islands,' the United States: and Africa?." In Japan, a similar clinical entity was then described and named HTLV-I-associated myelopathy (HAM)." Although an HTLV-I-like retrovirus has been isolated and partially 
HTLV-I integration is present in
A recent study' has shown that HTLV-I sequences can be detected in uncultured peripheral blood mononuclear cells (PBMC) of 11 patients with TSP/HTLV-I living in the US by using a gene amplification technique but not by using a classic Southern blot analysis. Thus, these authors suggested that the disease TSP/HTLV-I is not associated with a "large proviral DNA load."
In this report, we show without ambiguity by Southern blot analysis a polyclonal integration of HTLV-I proviral DNA in the genomic DNA of PBMC from 10 of 10 patients with TSP/HTLV-I living in France" and originating from the French West Indies, French Guiana, and Africa (Zaire and Central African Republic). Furthermore, we show the existence of a large number of proviral copies in our patients. This suggests that the frequent occurrence of the virus among the PBMC of such TSP/HTLV-I cases, irrespective of their geographical origin and of the duration of their clinical illnesses, might play an important role in the pathogenesis of this newly described clinico-virological entity.
MATERIALS AND METHODS
Three groups of patients were studied ( Table 1) . The first group comprised 10 patients (cases 1 to 10) who were diagnosed at Pitii-Salpitribre Hospital in Paris as suffering from TSPIHTLV-I based on the following clinical and biological disturbance and minimal sensory loss; (2) chronic and slowly progressive course with neither remission nor attack; (3) no personal or familial neurological antecedent; (4) nonsignificant abnormalities according to myelography or spinal imaging by computed tomography or nuclear magnetic resonance; and (5) presence of HTLV-Ispecific antibodies in serum and CSF.
The second group comprised three patients who were diagnosed as having acute ATL based on clinical, cytologic, and biological criteria (cases 11, 12, 13) .
The third and control group included five healthy HTLV-I sero-negative and three HTLV-I sero-positive women, one healthy and two with a smoldering ATL with specific cutaneous lesions and Peripheral blood was collected by venipuncture and PBMC were isolated on a Ficoll gradient (lymphoprep; Nyegaard, Norway). DNA extraction and Southern blotting were performed as de~cribed'~ on fresh or frozen (-SOOC) PBMC that had never been cultured. Nine micrograms of high molecular weight DNA were digested by EcoRI or PsrI restriction endonucleases under conditions recommended by the manufacturer (Promega Biotec, Madison, WI). The restriction fragments were separated in a 0.6% agarose gel by electrophoresis at 30 V for 36 hours and transferred to a hybridization nylon membrane (Hybond-N, Amersham, Little Chalfont, UK). The prehybridization and hybridization were performed at 42OC in 5 x SSC, sodium dodecyl sulfate (SDS) 0.5%, Denhart 1%, Dextran sulfate 5%, Formamide 50%. and sonicated denatured salmon sperm DNA at 200 pg/mL. After washing in high stringency conditions (1 x SSC, SDS 0.5% at 65OC), the blots were then exposed to X-ray film at -8OOC for 1 to 8 days.
Two different HTLV-I probes (kindly provided by M. Yoshida, Cancer Institute, Tokyo, Japan) were used: the pATK-06 subcloned BamHI-BamHI fragment of the pATK-1 clone, consisting of a part of the env region; and the pLTR-111 HindIII-Xho fragment of the pATK-1 clone, consisting of a part of the 3'LTR. The c myc probe (kindly provided by D. Stehelin, Lille, France) was a ClaI-Cia1 fragment of 1.4 kb corresponding to the third exon of human c myc.
Aliquots of 9 p g of uninfected human DNA were mixed with various amounts of HTLV-I viral DNA from an ATL patient (case 13) in ratio of viral genomes per human cell ranging from 2:l to 1:64. Assuming that 150 x lo3 cells represent 1 p g of DNA, this dilution corresponds to a Cells and molecular hybridization.
Probes.
Limits of sensitivity and quantification. range from 2.7 x lo6 to 2 x lo4 viral copies per sample of 9 p g . To quantify the HTLV-I DNA viral copies in the TSP/HTLV-I samples, the mixed DNA were treated as the DNA of TSP/HTLV-I and put on the same blot.
Study of PBMCsurface markers. The surface phenotype of the cells was determined by a standard method of indirect immunofluorescence" and cytofluorograph reading (model epic Profile; Coulter, Hialeah, FL) using a large panel of monoclonal antibodies (MoAbs) that recognize T-associated or T-restricted antigens (CD2, CD3, CD4, CD7, CD8) and B-restricted antigens (CD19, CD20). Other MoAbs were also used: CD25 (kindly provided by T. Waldman, Metabolism Branch, NCI, NIH, Bethesda, MD), CD33, CD41, anti-major histocompatibility complex (MHC) class I1 molecule DR, and WT31 (an antibody that recognizes a monomorphic part of the CD3 Ti ab-heterodimer). In all cases, the background fluorescence determined using irrelevant isotype mouse antibodies was lower than 5%.
Cell morphology was analyzed by light microscopy on May-Griinwald-Giemsa-stained PBMC. A total of 200 lymphocytes were assessed on each preparation and classified into four groups: normal lymphocytes, lymphocytes with an abnormally shaped nucleus (lobulated or grooved), typical ATL cells with foliated nuclei and hyperbasophilic cytoplasm, and large hyperbasophilic lymphoid cells with regular nucleus.
Morphological studies.
RESULTS
Integration of HTLV-I provirus in PBMC was analyzed by Southern blotting using an HTLV-I env probe. As six PstI restriction endonuclease sites are located inside the provirus (Fig l) , PstI digestion can be used to detect either polyclonal or monoclonal HTLV-I integration. In all the TSP/HTLV-I and the ATL cases, a clear band of the expected 2.3 kb size was observed (Fig 1) . To assess the sensitivity of the Southern method, dilutions of ATL DNA in an HTLV-Ifree DNA were performed and digested in parallel with TSP/HTLV-I DNA and included in the same gel. Hypothesizing that only one copy of HTLV-I proviral D N A is integrated in a cell, we can estimate that the number of (Fig I ) .
To determine if the mode of the integration of the HTLV-I provirus was clonal or polyclonal, EcoRI digests were analyzed. As no EcoRI sites are present inside the proviral genome, only clonal integration should be detected using this endonuclease (Fig I , ATL cases 1 and 2) . In TSP/HTLV-I DNA, no band was observed on the blot showing that proviral integration was polyclonal. This was confirmed using an LTR probe on PstI-digested DNAs (data not shown).
It is important to note that this random integration of the provirus in the PBMC DNA was found in all our patients, regardless of their geographical origin (French West Indies, French Guiana, or Africa), the duration of their clinical illnesses (mean = 6 years after onset; range, 1 to 12 years), or the titer of HTLV-I antibodies as determined by ELISA or PA tests ( Table 1) .
Phenotypic analysis of the PBMC from nine of the TSP/HTLV-I patients is shown in Table 2 . As deduced from the results obtained with antLCD2 and anti-CD3 MoAbs, the percentage of T cells ranged from 65% to 80% of Concerning the cytological analysis (Table 2) , lymphoid cells with an abnormally shaped nucleus were detected in 5%
to 15% (median, 9%) of the total lymphoid cells in all the patients. Furthermore, typical ATL-like cells with hyperconvoluted nuclei (flower cells) were seen in all but one case (case 4), representing 2% of the total lymphocytes. Neither lymphoid cells with abnormal nuclei nor typical ATL cells were seen in the HTLV-I negative controls. Large hyperbasophilic cells (1 % to 3%) were seen in the TSP patients and controls.
DISCUSSION
Using a Southern blot analysis, we show here that a polyclonal integration of HTLV-I proviral DNA can be detected in PBMC of patients with TSP/HTLV-I, regardless of their geographical origin, the duration of their clinical illnesses, or their HTLV-I antibody titers. Moreover, we estimated by dilution experiments that this HTLV-I polyclonal integration should be present in 3% to 15% of their PBMC.
In a recent work, Bhagavati et als have failed to detect by Southern blot such HTLV-I proviral DNA in PBMC of 11 patients with TSP/HTLV-I living in the United States, but were able to detect HTLV-I sequences by in vitro gene amplification. The conclusion of their study was that only a small proviral DNA load exists in TSP patients. The discrepancy between these observations and our results could be due to a difference in the Southern blot technique used for HTLV-I detection. In our study by dilution experiments, we were able to detect 4 x lo4 viral copies in 9 pg DNA (3% of HTLV-I positive cells). A difference in the HTLV-I probe used may also be involved. Finally, differences in geographical origin, duration of illness, or other genetic, environmental, or therapeutic factors may have modified the number of cells infected by HTLV-I in Bhagavati et al's patient population.
Our molecular results on TSP/HTLV-I are comparable to those briefly reported by Yoshida et aI2' who found a polyclonal integration of HTLV-I proviral DNA in peripheral blood lymphocytes of eight of nine Japanese patients with HAM. These data and ours are consistent with the recent proposition that TSP/HTLV-I and HAM are the same clinical entity.22 Thus, our results from 10 TSP/ HTLV-I cases originating from different geographical areas extends this similarity to the intracellular status of the provirus.
In Japanese or Caribbean HTLV-I sero-positive carrier~,2"~~ a small percentage (0.1% to 2%) of lymphoid cells with abnormal convoluted nuclei are found in their peripheral blood films. Most of these cells have been shown to be CD25+. However, it is important to note that in these healthy HTLV-I sero-positive subjects, viral integration is generally not detectable by Southern blot technique, probably due to the very low number of infected cells. All our 10 TSP/HTLV-I patients were found to have a mean value of 10% of abnormal lymphocytes. Most patients show a significant number of circulating DR-expressing T cells. It is worthwhile to note that some of these presumably activated T cells are CD25 + . Similar features have recently been found in Japanese HAM patients."
The nature of the cells infected by HTLV-I in our patients was not definitively assessed in this study. Although monocyte infection by the virus is not excluded, the concordance between the total number of abnormal lymphoid cells (range, 2% to 18%; mean, 10%) and the detection of HTLV-I viral copies in 3% to 15% of the patients' studied PBMC strengthens the hypothesis that the majority of the morphologically abnormal lymphoid cells of TSP/HAM may carry the HTLV-I proviral DNA randomly integrated in their DNA, and that these cells belong to DR-expressing T cell population. This hypothesis is also sustained by the fact that HTLV-I antigens detected by immunofluorescence in cultures derived from TSP/HTLV-I PBMC appear rapidly.'3s26 On the contrary, cultures derived from PBMC of healthy sero-positive carriers become positive less frequently and much later. It is unknown whether the infected cells are T4+ lymphocytes, as suggested by the slight excess of T4+ lymphocytes ( Table 2 ). The situation may be more complex. Recently, we have observed by double labeling that in two of our patients (cases 7 and 10) about half of the DR+ T cells were T8+, and half T4+ (A. Gessain, F. Siguax, unpublished data, May 1989). It is possible that these TS+ cells were induced to express DR by HTLV-I infection. Alternatively, these T8 activated cells may represent cytotoxic T lymphocytes. Whatever the explanation, the results obtained in our study are of interest with respect to the relationship between TSP/HAM and the other polyclonal states induced by A polyclonal integration of HTLV-I proviral DNA associated with few abnormal cells and a small increase of CD25 + cells have recently been described by Yamaguchi et a127 as an intermediate state between healthy carriers and smoldering ATL in HTLV-I sero-positive Japanese subjects. This blood picture is quite similar to that observed in our patients, although the clinical features are clearly distinct. Nearly all the Japanese patients had minor disease, such as Strongyloides stercoralis infection, but no neurological signs, while TSP/HTLV-I patients suffer from a chronic progressive myelopathy. Furthermore, Yamaguchi suggests that patients with intermediate state disease might be at risk to develop ATL. In this context, it is important to point out that none of our patients have developed ATL despite a mean follow-up of 6 years, and that, in general, the concomitant occurrence of ATL and TSP/HAM is an exceptional event.16 HTLV-I.
